LX2932

LX2932 is an orally active LX2931 (HY-14370) analogue and S1P/S1PR signaling axis modulator. LX2932 yields a dose-dependent decrease in circulating lymphocyte numbers. LX2932 improves collagen-induced arthritis[1][2].

Product Specifications

CAS Number

[1055027-48-9]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Drug Derivative; LPL Receptor

Related Pathways

GPCR/G Protein; Others

Field of Research

Inflammation/Immunology

Smiles

[C@@H]([C@@H]([C@@H](CO)O)O)(O)C=1NC(=NC1)C=2C=CON2

Molecular Formula

C10H13N3O5

Molecular Weight

255.23

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Bagdanoff JT, et al. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E) -1- (4- ((1R,2S,3R) -1,2,3,4-tetrahydroxybutyl) -1H-imidazol-2-yl) ethanone oxime (LX2931) and (1R,2S,3R) -1- (2- (isoxazol-3-yl) -1H-imidazol-4-yl) butane-1,2,3,4-tetraol (LX2932) . J Med Chem. 2010 Dec 23;53 (24) :8650-62. |[2]Gao Y, et al. Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm (2020) . 2024 Mar 10;5 (3) :e509.